KK Shiseido header image

KK Shiseido

4911

Equity

ISIN JP3351600006 / Valor 763285

Tokyo Stock Exchange (2024-09-18)
JPY 3,347.00+0.27%

KK Shiseido
UMushroom community rating:

star star star star star
4.43 7 votes No rating yet
NegativeNeutralPositive

About company

KK Shiseido, established in 1872 in Ginza, Tokyo, began as Japan's first Western-style pharmacy and has since evolved into a leading global beauty company. Operating in approximately 120 countries and regions, Shiseido is renowned for its innovative approach to beauty and skincare, consistently setting industry standards with its pioneering products. The company focuses on creating unique beauty solutions that transcend traditional cosmetics, aiming to deliver new values and enhance customer satisfaction worldwide. With a strong foundation in Japan, Shiseido continues to expand its influence and offerings, maintaining a steadfast commitment to innovation and excellence in the beauty industry.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (07.08.2024):

Q1 2024 Revenue Growth

KK Shiseido reported a year-over-year net sales growth of 3% on a like-for-like basis in Q1 2024. This growth was achieved despite challenges such as treated water release effects and inventory adjustments in the China and Travel Retail Businesses.

Core Operating Profit

In Q1 2024, KK Shiseido achieved a core operating profit of JPY 11.3 billion. This was a significant milestone, reflecting the company's successful implementation of structural reforms and strategic marketing investments.

Japan Business Performance

KK Shiseido's Japan Business saw accelerated growth in Q1 2024, with core brands achieving growth in the high 20% range and hero products exceeding 30% growth. This performance was driven by increased market share and effective sales generation through balanced investment allocation.

China Market Share

In Q1 2024, KK Shiseido increased its market share in the prestige category in China. This was attributed to strategic marketing investments aimed at maximizing market recovery and capturing consumer interest in high-end products.

E-commerce Growth

KK Shiseido's e-commerce sales in Q1 2024 grew significantly, reaching the high 20% range. This marked a substantial acceleration from the lower 10% growth seen in FY2023, driven by strategic plans to strengthen Retail.com, expand into Pure Players, and enhance Owned.com platforms.

Summarized from source with an LLMView Source

Key figures

-41.2%1Y
-57.7%3Y
-61.7%5Y

Performance

40.5%1Y
34.7%3Y
33.3%5Y

Volatility

Market cap

9481 M

Market cap (USD)

Daily traded volume (Shares)

2,372,500

Daily traded volume (Shares)

1 day high/low

3396 / 3320

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.43

7 votes
Performance:
starstarstarstarstar
4.29
Innovation:
starstarstarstarstar
4.14
Society:
starstarstarstarstar
4.14
Nature:
starstarstarstarstar
4.14
Robin Roten
Switzerland, 19 Dec 2022
star star star star star
Joseph WI Gospodinov
Switzerland, 05 Jul 2022
star star star star star
Thomas Swiatek
Switzerland, 04 Jul 2022
star star star star star
Good company with high brand value. Definitely one of the more interesting Kabushiki Gaishas!

EQUITIES OF THE SAME SECTOR

Camurus AB
Camurus AB Camurus AB Valor: 30510553
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.15%SEK 663.00
4basebio PLC
4basebio PLC 4basebio PLC Valor: 112829117
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 17.10
Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc Amphastar Pharmaceuticals Inc Valor: 24511852
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.34%USD 49.78
Cassava Sciences Inc
Cassava Sciences Inc Cassava Sciences Inc Valor: 46983284
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.13%USD 30.32
Oncopeptides AB
Oncopeptides AB Oncopeptides AB Valor: 35671972
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.46%SEK 2.09
dentalcorp Holdings Ltd
dentalcorp Holdings Ltd dentalcorp Holdings Ltd Valor: 111405816
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.80%CAD 8.17
Unitedhealth Group Inc
Unitedhealth Group Inc Unitedhealth Group Inc Valor: 1078451
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.47%USD 580.65
Johnson & Johnson
Johnson & Johnson Johnson & Johnson Valor: 943981
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.55%USD 166.15
Pfizer Inc
Pfizer Inc Pfizer Inc Valor: 962004
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.27%USD 29.75
Abbott Laboratories
Abbott Laboratories Abbott Laboratories Valor: 903037
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.75%USD 114.88